These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28257549)

  • 21. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of oral oxymorphone in the elderly.
    Guay DR
    Consult Pharm; 2007 May; 22(5):417-30. PubMed ID: 17658959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral oxymorphone (Opana).
    Med Lett Drugs Ther; 2007 Jan; 49(1251):3-4. PubMed ID: 17179898
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical opioid use among oral and intravenous users in Australia: A qualitative comparative study.
    Dertadian G; Iversen J; Dixon TC; Sotiropoulos K; Maher L
    Int J Drug Policy; 2017 Mar; 41():51-58. PubMed ID: 28107670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxymorphone--Endo/Penwest: EN 3202, EN 3203.
    Drugs R D; 2003; 4(3):204-6. PubMed ID: 12757410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review.
    Sloan PA; Barkin RL
    J Opioid Manag; 2008; 4(3):131-44. PubMed ID: 18717508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK; Babul N; Ahdieh H
    Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral oxymorphone for pain management.
    Chamberlin KW; Cottle M; Neville R; Tan J
    Ann Pharmacother; 2007 Jul; 41(7):1144-52. PubMed ID: 17595308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes.
    Pfister GJ; Burkes RM; Guinn B; Steele J; Kelley RR; Wiemken TL; Saad M; Ramirez J; Cavallazzi R
    J Crit Care; 2016 Oct; 35():29-32. PubMed ID: 27481733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of rhabdomyolysis associated with severe opioid withdrawal.
    Gangahar D
    Am J Addict; 2015 Aug; 24(5):400-2. PubMed ID: 26095066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty.
    Ahdieh H; Ma T; Babul N; Lee D
    J Clin Pharmacol; 2004 Jul; 44(7):767-76. PubMed ID: 15199081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Geriatric patients with known acute kidney injury and normal renal function at the time of admittance to the intensive care unit/assessment of RRT requirement and mortality: retrospective case-control study.
    Karakose F; Akkoyunlu ME; Erkoc R; Kansu A; Bayram M; Sezer M; Ozcelik H; Kart L
    Wien Klin Wochenschr; 2015 Apr; 127(7-8):290-6. PubMed ID: 25586443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study.
    McIlwain H; Ahdieh H
    Am J Ther; 2005; 12(2):106-12. PubMed ID: 15767827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical applications of oxymorphone.
    Vadivelu N; Maria M; Jolly S; Rosenbloom J; Prasad A; Kaye AD
    J Opioid Manag; 2013; 9(6):439-52. PubMed ID: 24481932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxymorphone: a review.
    Prommer E
    Support Care Cancer; 2006 Feb; 14(2):109-15. PubMed ID: 16317569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Prescription Opioid Misuse/Abuse as Determined by International Classification of Diseases Codes: A Systematic Review.
    Roland CL; Lake J; Oderda GM
    J Pain Palliat Care Pharmacother; 2016 Dec; 30(4):258-268. PubMed ID: 27802072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Psychopathology of the misuse of Subutex®: The Popeye syndrome].
    Békaert J; Podevin G
    Encephale; 2015 Jun; 41(3):229-37. PubMed ID: 25212472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.
    Sloan P; Slatkin N; Ahdieh H
    Support Care Cancer; 2005 Jan; 13(1):57-65. PubMed ID: 15538638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.